OncoMethylome's Partner Veridex Licenses Prostate Cancer Methylation Technology to Laboratory Corporation of America Holdings
01-Jun-2007
The prostate cancer marker and methylation technology required to detect it were initially developed by OncoMethylome Sciences and were licensed to Veridex in a commercial deal that was announced on January 19, 2005. LabCorp is the first fullservice, national clinical laboratory in the U.S. to access this new technology. Terms of the agreement were not disclosed.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
With the Flick of a Switch: Shaping Cells with Light - The therapeutic potential of this research is immense
Go to page
Gronemeyer Maschinenfabrik GmbH & Co. - Höxter, Germany
Go to page
On the trail of cancer stem cells - What goes on inside and between individual cells during the very earliest stages of tumor development?
Go to page
Angiogenesis_inhibitor
Go to page
Dens_evaginatus
Go to page
Pineal_gland
Go to page
Chlorosome
Go to page
Benzedrine
Go to page